Pancreatic cancer develops through a web of risk factors rather than a single cause, and most of them interact with each other in ways researchers are still untangling. Smoking, obesity, long-standing diabetes, chronic pancreatitis, and inherited gene mutations are the best-established contributors, but the list extends to less obvious influences like blood type and gum disease. What makes the picture tricky is that some of these factors, particularly diabetes, can be both a cause of pancreatic cancer and an early symptom of it.
Smoking Is the Strongest Modifiable Risk Factor
If you had to pick one lifestyle factor most reliably tied to pancreatic cancer, it would be smoking. A large international consortium analysis found that current smokers had roughly double the risk compared with people who never smoked, and heavy smokers (35 or more cigarettes per day) had about three and a half times the risk, with a clear dose-response trend.1PubMed Central. Cigarette smoking and pancreatic cancer: an analysis from the International Pancreatic Cancer Case-Control Consortium (Panc4) The risk climbs with duration too, peaking around 40 years of smoking.
The encouraging finding is that quitting matters. The consortium data showed risk dropping back toward baseline after about 20 years of cessation. A multiethnic cohort study confirmed the pattern from a different angle: every year after quitting reduced the excess risk from cumulative pack-years by roughly 9%.2PubMed Central. Excess pancreatic cancer risk due to smoking and modifying effect of quitting smoking: The Multiethnic Cohort Study That same study found that 50 pack-years of smoking was associated with a 91% increased risk compared to never-smokers. The practical takeaway is straightforward: a long smoking history raises your risk substantially, and the sooner you stop, the more of that excess risk you shed over time.
Excess Body Fat and Where You Carry It
Obesity is consistently linked to pancreatic cancer, though the effect is more modest than smoking. A meta-analysis of prospective studies found that every five-unit increase in body mass index was associated with about a 10% increase in risk, and the relationship held similarly for men and women.3Annals of Oncology. Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose–response meta-analysis of prospective studies Waist circumference and waist-to-hip ratio showed associations as well, suggesting that abdominal fat may be particularly relevant. A 10-centimeter increase in waist circumference was linked to an 11% higher risk, and a 0.1-unit rise in waist-to-hip ratio corresponded to a 19% increase.
One large prospective study from the Nurses’ Health Study and the Health Professionals Follow-up Study explored whether being overweight at a younger age matters independently.4JAMA. Physical Activity, Obesity, Height, and the Risk of Pancreatic Cancer There were hints of elevated risk in both women and men who had higher BMIs in their late teens or early twenties, but once current BMI was accounted for, the early-life association faded. In other words, what seems to matter most is carrying excess weight now, not what you weighed decades ago.
Diabetes as Both a Risk Factor and an Early Warning
The relationship between diabetes and pancreatic cancer runs in two directions, which makes it uniquely confusing. Long-standing type 2 diabetes, present for five years or more, is an independent risk factor for pancreatic cancer. Multiple studies estimate the excess risk at around 50% compared to people without diabetes.5PubMed Central. Association between pancreatic cancer and diabetes: insights from a retrospective cohort study The suspected mechanism involves chronic high insulin levels within the pancreas itself, which promote cell growth and survival in nearby tissue.6PubMed. The bidirectional link between diabetes and pancreatic cancer
But new-onset diabetes in an older adult can also be a red flag that a pancreatic tumor is already present. Up to 80% of people diagnosed with pancreatic cancer turn out to have elevated blood sugar or full-blown diabetes, and this can be detectable before any other symptoms appear.7PubMed Central. The early diagnosis of pancreatic cancer and diabetes: what’s the relationship? Older patients with new-onset diabetes carry about an eightfold higher risk of harboring pancreatic cancer compared with the general population.8PubMed Central. New-onset diabetes: a potential clue to the early diagnosis of pancreatic cancer And when the tumor is surgically removed, the diabetes often improves, reinforcing the idea that the cancer itself was driving the metabolic disruption.
This two-way street matters for anyone over 50 who develops unexpected diabetes without the usual risk profile. It does not mean that new diabetes is likely to be cancer. Pancreatic cancer is still relatively rare. But an unexplained change in blood sugar that does not fit the typical type 2 pattern may warrant closer attention, especially if accompanied by weight loss or digestive symptoms.
Chronic Pancreatitis
Chronic pancreatitis, the condition in which the pancreas is persistently inflamed and scarred, is one of the strongest recognized risk factors. People with hereditary forms of pancreatitis carry particularly high cumulative risks: about 19% by age 60 for those with mutations in the PRSS1 gene and about 12% for those with SPINK1 mutations.9PubMed Central. Pancreatic Cancer in Chronic Pancreatitis: Pathogenesis and Diagnostic Approach Even so, pancreatic cancer developing from chronic pancreatitis remains a relatively rare event overall. Most people with chronic pancreatitis will not develop cancer, but the ongoing inflammation creates an environment that can accelerate the accumulation of genetic damage over decades.
Family History and Inherited Mutations
A family history of pancreatic cancer is one of the more powerful predictors, especially when multiple close relatives are affected. A prospective study of families with known clustering of the disease found that having one first-degree relative with pancreatic cancer raised risk about four and a half fold. Two affected first-degree relatives pushed the risk up to about six fold, and three or more affected first-degree relatives meant a 32-fold increase.10Cancer Research. Prospective Risk of Pancreatic Cancer in Familial Pancreatic Cancer Kindreds Spouses and other genetically unrelated members of the same families did not share the elevated risk, confirming this is driven by inherited factors rather than shared environment.
Specific gene mutations have been identified in a fraction of these families. In one study of familial pancreatic cancer, about 8% of affected family members carried damaging mutations in BRCA1, BRCA2, PALB2, or CDKN2A, compared to about 3.5% in nonfamilial cases.11Genetics in Medicine. BRCA1, BRCA2, PALB2, and CDKN2A mutations in familial pancreatic cancer: a PACGENE study BRCA2 was the most frequently mutated of the four genes. A separate analysis of pancreatic tumors found BRCA-pathway mutations in about 29% of cases, with the vast majority in BRCA2.12Scientific Reports. Mutations in BRCA1, BRCA2, and PALB2, and a panel of 50 cancer-associated genes in pancreatic ductal adenocarcinoma
Lynch syndrome, the most common hereditary cancer predisposition syndrome, also contributes a modest risk. A nationwide cohort study found that people with Lynch syndrome had a cumulative pancreatic cancer incidence of about 1.2% by age 75, with the highest risk (about 2.1%) in those with MSH2 mutations, which translated to roughly a threefold relative risk compared to the general population.13The Lancet. Pancreatic, ampullary, and distal cholangiocarcinoma risk and survival in Lynch syndrome: a nationwide cohort study The risk was essentially zero in PMS2 mutation carriers. Genetic testing can be valuable in families with a pattern of pancreatic or related cancers, because identifying a specific mutation may open the door to targeted screening or treatment strategies.
Blood Type
One of the more surprising and less well-known risk factors involves ABO blood group. A large prospective study found that people with non-O blood types had a higher risk of developing pancreatic cancer compared with those with type O blood. The highest risk was in type B (about 72% higher), followed by type AB (about 51% higher) and type A (about 32% higher).14PubMed Central. ABO Blood Group and the Risk of Pancreatic Cancer Overall, the researchers estimated that about 17% of pancreatic cancer cases were attributable to having a non-O blood type. A Chinese population-based study confirmed similar patterns, showing about a twofold increased risk for blood type A and a similar elevation for type AB.15PubMed Central. ABO Blood Group and Diabetes Mellitus Influence the Risk for Pancreatic Cancer in a Population from China
The mechanism is not fully understood, but ABO antigens are expressed on the surface of many cell types including pancreatic cells, and they may influence inflammation and immune surveillance. Obviously, you cannot change your blood type, so this is not an actionable risk factor. It is, however, an interesting piece of the puzzle that may eventually help with risk stratification models.
Alcohol and Binge Drinking
Alcohol’s link to pancreatic cancer is more nuanced than you might expect. Light to moderate drinking does not appear to carry much risk, but heavy and prolonged consumption does, particularly in men. A population-based study found that men who reported binge drinking had about three and a half times the risk, with a clear dose-response by number of drinks per day and years of binge drinking.16PubMed Central. Risk of pancreatic cancer by alcohol dose, duration, and pattern of consumption, including binge drinking: a population-based study The pattern of consumption seemed to matter as much as total volume. The same associations were not significant in women in that study, though researchers noted smaller sample sizes may have played a role. Heavy alcohol intake also promotes chronic pancreatitis, which itself is a risk factor, so the pathways may compound each other.
Gum Disease and Oral Bacteria
This is one of the more unexpected connections to emerge in recent years. A systematic review of 13 studies found a consistent association between periodontal disease and increased pancreatic cancer prevalence.17PubMed Central. Could Periodontitis Increase the Risk of Suffering from Pancreatic Cancer?—A Systematic Review More specifically, a prospective nested case-control study identified two oral pathogens, Porphyromonas gingivalis and Aggregatibacter actinomycetemcomitans, as significantly associated with higher pancreatic cancer risk. The presence of P. gingivalis was linked to about 60% higher odds, while A. actinomycetemcomitans roughly doubled the odds.18Gut. Human oral microbiome and prospective risk for pancreatic cancer: a population-based nested case-control study A more recent study in JAMA Oncology confirmed that P. gingivalis and other periodontal pathogens were associated with increased risk.19JAMA Oncology. Oral Bacterial and Fungal Microbiome and Subsequent Risk for Pancreatic Cancer
The proposed mechanisms include chronic low-grade systemic inflammation triggered by gum disease and the direct effects of bacterial toxins that can reach the pancreas through the bloodstream. This does not mean that brushing your teeth prevents pancreatic cancer, but it adds to a growing understanding that chronic infections and inflammation play a background role in many cancers. Helicobacter pylori, a stomach bacterium, has also been investigated. One prospective study found no overall association but did find a roughly fourfold elevated risk among never-smokers who were seropositive for H. pylori, though that subgroup finding was based on small numbers.20PubMed Central. A prospective study of Helicobacter pylori in relation to the risk for pancreatic cancer
Workplace and Environmental Chemical Exposures
Certain occupational exposures have been linked to pancreatic cancer, though this area of research is harder to pin down because exposures are often self-reported and overlapping. A case-control study found elevated odds for regular exposure to pesticides (about 21% higher), asbestos (about 54% higher), benzene (about 70% higher), and chlorinated hydrocarbons (about 63% higher) after adjusting for smoking, diabetes, and other factors.21PubMed Central. Exposure to environmental chemicals and heavy metals, and risk of pancreatic cancer
Chlorinated hydrocarbons have accumulated the most evidence. Multiple meta-analyses have found elevated risk, with one Bayesian analysis estimating roughly double the risk for occupationally exposed workers. Occupations with the strongest associations include metal degreasers and dry cleaners.22PubMed Central. Occupational Risk Factors and Pancreatic Cancer: A Review of Recent Findings DDT and organochlorines have also shown associations in smaller studies, though many of these involved historical exposures that are less common today. Cadmium, a heavy metal present in cigarette smoke and certain industrial processes, has suggestive but inconsistent evidence.
Dietary Factors Are Surprisingly Weak
Despite popular assumptions, the connection between specific foods and pancreatic cancer is weaker than for many other cancers. A meta-analysis specifically examining red and processed meat found no significant relationship with pancreatic cancer risk.23PubMed Central. Red and processed meat and pancreatic cancer risk: a meta-analysis This may surprise people who associate processed meat with cancer generally, but the evidence so far suggests that whatever link processed meat has to colorectal cancer does not clearly extend to the pancreas. The obesity pathway remains the dominant dietary-related mechanism: eating patterns that promote weight gain and insulin resistance matter more than individual food items.
Demographic Trends and the Rise in Younger Women
Pancreatic cancer has historically been considered a disease of older men. That picture is shifting. A U.S. analysis covering 2000–2018 found that among people 55 and older, incidence increased faster in men than women. But in people under 55, the trend reversed. Women under 55 saw a significantly greater relative increase in incidence than men in the same age range. The effect was most dramatic among 15-to-34-year-olds, where the annual increase in women was nearly double the rate in men.24JAMA. Incidence of Pancreatic Cancer by Age and Sex in the US, 2000-2018 A follow-up analysis confirmed that this rise in younger women was driven specifically by adenocarcinoma, the most common and lethal type, rather than by less aggressive neuroendocrine tumors.25PubMed Central. The Disproportionate Rise in Pancreatic Cancer in Younger Women Is Due to a Rise in Adenocarcinoma and Not Neuroendocrine Tumors
The reasons for this disproportionate rise are not yet clear. Rising obesity rates in younger women, changes in smoking patterns, and hormonal factors have all been proposed, but none fully account for the gap. This trend is still relatively recent, and the absolute numbers remain small since pancreatic cancer in people under 55 accounts for only about 11% of total cases. Still, it represents a genuine epidemiological puzzle.
Hormonal and Reproductive Factors in Women
Given the sex-based trends described above, researchers have looked more closely at hormonal influences. The findings are mixed but interesting. A population-based study found that women who used menopausal hormone therapy had a roughly 23% lower risk of pancreatic cancer, and longer use was associated with greater reduction: about 60% lower risk with three or more years of use.26PubMed Central. Menopausal hormone therapy and pancreatic cancer risk in women: a population-based matched cohort study A separate cohort study found that current users of estrogen-only therapy had about 41% lower risk, but estrogen-plus-progestin therapy showed no association. Interestingly, long-term oral contraceptive use (10 or more years) was linked to a higher risk in that same study.27American Journal of Epidemiology. Reproductive Factors, Exogenous Hormones, and Pancreatic Cancer Risk in the CTS
A large consortium analysis from the Panc4 group found that women who had undergone hysterectomy had about a 22% lower risk, particularly when combined with hormone replacement therapy.28PubMed Central. Menstrual and Reproductive Factors, Hormone Use and Risk of Pancreatic Cancer: Analysis From the International Pancreatic Cancer Case-Control Consortium (Panc4) Basic reproductive factors like age at first period, number of pregnancies, and age at menopause have not shown consistent associations. The hormonal picture remains incomplete, and estrogen’s potential protective role may involve its effects on insulin sensitivity and inflammation, but this is still speculative.
Precursor Lesions Worth Knowing About
Pancreatic cancer does not always arise out of nowhere. Some tumors develop from identifiable precursor lesions, particularly cystic growths in the pancreas that are increasingly discovered on imaging done for unrelated reasons. The two most important types are intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms (MCNs). Together, these give rise to about 8% of pancreatic cancers.29PubMed Central. A Review of the Diagnosis and Management of Premalignant Pancreatic Cystic Lesions
The tricky part is that most of these cysts are benign and never cause problems. A long-term study tracking patients with IPMNs over a median follow-up of 12 years found that only 4 out of 231 patients developed pancreatic cancer.30JAMA Network Open. Long-Term Outcomes and Risk of Pancreatic Cancer in Intraductal Papillary Mucinous Neoplasms About 41% of cysts grew slightly on follow-up imaging, but progression to high-risk features was uncommon. This means that if you are told you have a pancreatic cyst, the most likely outcome is years of stable surveillance with no intervention needed. People with long-standing diabetes on top of IPMNs face a higher risk of concurrent cancer.31PubMed Central. Long-standing diabetes mellitus increases concomitant pancreatic cancer risk in patients with intraductal papillary mucinous neoplasms
Gallstones and Cholecystectomy
Gallstones and gallbladder removal have appeared in some studies as associated with pancreatic cancer, but this link has a major caveat. A large Korean cohort study found that both gallstones and cholecystectomy were associated with roughly double the risk of hepatobiliary and pancreatic cancers overall. However, when the researchers applied lag periods of one, three, and five years, the excess risk essentially disappeared.32PubMed Central. Gallstones, Cholecystectomy and the Risk of Hepatobiliary and Pancreatic Cancer: A Nationwide Population-based Cohort Study in Korea That pattern suggests the association is largely due to detection bias: gallstone workups lead to scans that catch tumors that were already there. A Swedish study did find a modest but persistent elevation of about 30% for pancreatic cancer five or more years after cholecystectomy, so a small long-term effect cannot be ruled out entirely.33PubMed Central. Gallstones, cholecystectomy and risk of cancers of the liver, biliary tract and pancreas
Screening for High-Risk Groups
For the general population, there is no recommended screening test for pancreatic cancer. The disease is uncommon enough that screening everyone would produce far more false alarms than genuine catches. But for people with strong family histories or known genetic mutations, screening programs using MRI and endoscopic ultrasound are being explored. A multicentre comparative study found that both EUS and MRI can detect precursor lesions and early-stage disease in high-risk individuals, though neither test is perfect on its own.34Gut. A multicentre comparative prospective blinded analysis of EUS and MRI for screening of pancreatic cancer in high-risk individuals Advances in MRI technology continue to improve the ability to detect small lesions.35PubMed Central. Screening for pancreatic cancer in high-risk individuals using MRI: optimization of scan techniques to detect small lesions
Who qualifies as “high risk” in this context? Generally, people with two or more first-degree relatives with pancreatic cancer, carriers of BRCA2, PALB2, or CDKN2A mutations with a family history of the disease, or those with hereditary pancreatitis. Screening typically begins around age 50, or 10 years before the youngest case in the family, and involves annual imaging. The goal is to catch cancers at a resectable stage, when surgery still has a chance of being curative, or to identify precursor lesions before they turn malignant.
Experimental Chemoprevention With Common Drugs
Statins and metformin, two inexpensive and widely prescribed drugs, have attracted attention as potential preventive agents. Preclinical research has shown that statins exhibit antitumor effects in pancreatic cancer cell lines and animal models, including slowing the progression of precancerous lesions.36PubMed Central. Statins and pancreatic cancer A recent animal study found that low-dose metformin and simvastatin given together, but not individually, reduced fibro-inflammation and delayed development of advanced precancerous changes in obese male mice engineered to develop pancreatic cancer.37Scientific Reports. Low dosage combination treatment with metformin and simvastatin inhibits obesity-promoted pancreatic cancer development in male KrasG12D mice The combination also reduced proliferation in precancer cells and inhibited key molecular pathways involved in tumor growth.
These are animal data and early-stage findings, not clinical recommendations. No large randomized trial has yet demonstrated that taking statins or metformin prevents pancreatic cancer in humans. But the biology is compelling enough that clinical trials exploring these drugs for chemoprevention in high-risk populations are being discussed. For people already taking these medications for cholesterol or diabetes management, the potential ancillary benefit is an interesting silver lining, though hardly a reason to start medication on its own.